Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(CLNO, PWRM, SLTC, APRI, CPIX) Stock under Consideration by Stock-PR.com

Stock-PR Reporting

stockpr_logo-site

 

FREE Daily Stock Alerts From Stock-PR.com

chartstockalert

http://pennyomega.com/img/clno.jpg Cleantech Transit Inc. (OTCPK:CLNO)

Municipal sewage contains organic biomass solids, and many wastewater treatment plants use anaerobic digestion to reduce the volume of these solids. Anaerobic digestion stabilizes sewage sludge and destroys pathogens. Sludge digestion produces biogas containing 60-percent to 70-percent methane. Most wastewater treatment plants that use anaerobic digesters burn the gas for heat to maintain digester temperatures and to heat building space. Unused gas is burned off as waste but could be used for fuel in an engine-generator or fuel cell to produce electric power.

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (
www.phoenixenergy.net). This project can generate shareholder returns as well benefit the Company's manufacturing clients worldwide. Cleantech Transit Inc. is in the business of producing and conserving power. It produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind.

Cleantech Transit Inc. is pleased to provide additional details after achieving success on the 500 KW facility and successfully moving past the interconnection testing stage.

Coming on the recent success at the 500KW facility in Merced, California this poises Phoenix Energy to become a leading developer of renewable biomass distributed generation plants that utilize local resources for local energy.

Cleantech will be providing details on the expecting closing date of its initial investment into Phoenix Energy in the coming weeks.

Please visit Cleantech Transit, Inc. website www.cleantechtransitinc.com.

**************************

pwrm_logo_200x721 Power3 Medical Products, Inc. (OTC:PWRM)

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

Parkinson's disease causes problems in the nerve cells in the brain that control muscle movement. Nerve cells that make a chemical called dopamine normally send signals that help coordinate your movements. In people who have Parkinson's disease, these cells die or do not work properly. The disease's effects get worse over time.

The NuroPro Blood Test is Power3's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.

Please visit Power3 Medical Products, Inc website http://www.power3medical.com

***********************************

Selectica Inc. (Nasdaq:SLTC) announced winners of the Selectica Superstar Awards, presented at Fusion '11, Selectica's annual contract management summit. "These awards honor teams that have made exceptional contributions to their companies through the innovative use of Selectica solutions," said Allen Pogorzelski, Vice President of Marketing at Selectica. "The number of nominations and the noteworthy accomplishments of our customers made the final selection very difficult. The professionals recognized here have delivered outstanding results in helping their companies achieve business goals such as closing business faster, eliminating risk, improving margins, and gaining greater compliance."

Selectica provides Global 2000 companies with deal management solutions to help companies close business faster, with higher margins and lower risk. Selectica offers tightly integrated applications for guided selling, sales configuration, pricing, quoting, and contract lifecycle management, including modules for mobile devices and employee self-service.

***********************

Apricus Biosciences, Inc. (Nasdaq:APRI) announced that Steve Martin has been appointed Senior Vice President and Chief Financial Officer, replacing Mark Westgate, who will serve as a consultant to the Company during a transition period. Mr. Martin, a certified public accountant, brings over 25 years of financial leadership to Apricus Bio, with significant expertise in growing public companies in a variety of industries, including the life sciences. Since 2008, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly-traded software company.

Apricus Biosciences, Inc., through its Bio-Quant, Inc. subsidiary, engages in the design and development of pharmaceutical products, as well as provision of pre-clinical contract research organization services.

***********************

Cumberland Pharmaceuticals, Inc. (Nasdaq:CPIX) a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, announced that it will present a corporate overview at the Wells Fargo Securities Healthcare Conference in Boston at 2:30 p.m. Eastern Time on Wednesday, June 22, 2011. The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (OTCPK:CLNO). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg